Announcements Trials
Browse Landscape

Phase

Phase 4 9Phase 1 6Phase 2 3Phase NA 2Phase 3 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Zollinger-Ellison Syndrome 1Precancerous Conditions 1Esophageal Neoplasms 1Barrett Esophagus 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Esomeprazole × Clear all
NCT00357682 2025-05-01

AspECT

University of Oxford

Phase 3 Completed
2,557 enrolled 17 charts
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

NCT00079833 2010-11-19

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

AstraZeneca

Phase 3 Completed
25 enrolled

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡